| 336 | 1 | 133 |
| 下载次数 | 被引频次 | 阅读次数 |
人类T细胞白血病1型病毒（Human T-cell leukemia virus type 1, HTLV-1）是一种与成人T细胞白血病（Adult T-cell leukemia, ATL）等人类疾病密切相关的逆转录病毒。本文从HTLV-1病毒及其致病机制出发，介绍了一线抗病毒治疗、化学疗法、造血干细胞移植等常规抗病毒策略，并探讨了免疫调节剂、单克隆抗体、分子靶向治疗、治疗性疫苗等新型手段的研究进展，期望为抗HTLV-1病毒感染及ATL的临床治疗提供科学指导。
Abstract：Human T-cell leukemia virus type 1(HTLV-1) is a retrovirus that is closely related to adult T-cell leukemia(ATL) and other human diseases. Based on HTLV-1 virus and its pathogenic mechanism, this article introduces the conventional antiviral strategies such as first-line antiviral therapy, chemotherapy and hematopoietic stem cell transplantation, and discusses the research progress of new methods such as immunomodulators, monoclonal antibodies, molecular targeted therapy and therapeutic vaccines. We hope to provide scientific guidance for the clinical treatment of anti-HTLV-1 infection and ATL.
[1] Zuo X, Zhou R, Yang S, et al. HTLV-1 persistent infection and ATLL oncogenesis[J]. J Med Virol,2023, 95(1):e28424. DOI:10. 1002/jmv. 28424.
[2]陶玲，杨丽，王辉.人T细胞白血病病毒1型/人嗜T细胞病毒1型（HTLV-1）及其与相关疾病关系的研究进展[J].细胞与分子免疫学杂志，2019, 35(1):89-94. DOI:10. 13423/j. cnki. cjcmi. 008749.
[3] Forlani G, Shallak M, Accolla RS, et al. HTLV-1infection and pathogenesis:new insights from cellular and animal models[J]. Int J Mol Sci, 2021, 22(15):8001. DOI:10. 3390/ijms22158001.
[4] Li L, Ou S, Huang C, et al. The prevalence of human T-cell leukemia virus in blood donors in China[J].Transfusion, 2019, 59(7):2361-2367. DOI:10. 1111/trf. 15309.
[5] Nakano N, Nakasone H, Fuji S, et al. Outcomes in human T-cell leukemia virus type I carriers after hematopoietic stem cell transplantation for diseases other than adult T cell leukemia/lymphoma:a Japanese national survey[J]. Lancet Reg Health West Pac,2023, 40:100902.DOI:10. 1016/j.lanwpc. 2023. 100902.
[6]林莺，张荣东，陈仁利，等.化疗联合抗病毒治疗成人T细胞白血病/淋巴瘤的临床研究[J].中国实验血液学杂志，2022, 30(5):1407-1414. DOI:10. 19746/j.cnki. issn1009-2137. 2022. 05. 016.
[7] Matsuoka M. Human T-cell leukemia virus type I(HTLV-I)infection and the onset of adult T-cell leukemia(ATL)[J]. Retrovirology, 2005, 2(1):27.DOI:10. 1186/1742-4690-2-27.
[8] Manel N, Kim FJ, Kinet S, et al. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV[J]. Cell, 2003, 115(4):449-459. DOI:10. 1016/S0092-8674(03)00881-X.
[9] Jones KS, Petrow-Sadowski C, Huang YK, et al. Cellfree HTLV-1 infects dendritic cells leading to transmission and transformation of CD4+T cells[J].Nat Med, 2008, 14:429-436. DOI:10. 1038/nm1745.
[10]Mesnard JM, Barbeau B, Césaire R, et al. Roles of HTLV-1 basic zip factor(HBZ)in viral chronicity and leukemic transformation. potential new therapeutic approaches to prevent and treat HTLV-1-related diseases[J]. Viruses, 2015, 7(12):6490-6505. DOI:10. 3390/v7122952.
[11]Matsuoka M, Jeang KT. Human T-cell leukemia virus type 1(HTLV-1)and leukemic transformation:viral infectivity, Tax, HBZ and therapy[J]. Oncogene,2011, 30(12):1379-1389. DOI:10. 1038/onc. 2010. 537.
[12]Zhao T. The role of HBZ in HTLV-1-induced oncogenesis[J]. Viruses, 2016, 8(2):E34. DOI:10. 3390/v8020034.
[13]Ma G, Yasunaga J, Matsuoka M. Multifaceted functions and roles of HBZ in HTLV-1 pathogenesis[J]. Retrovirology, 2016, 13:16. DOI:10. 1186/s12977-016-0249-x.
[14]Polakowski N, Sarker MAK, Hoang K, et al. HBZ upregulates myoferlin expression to facilitate HTLV-1infection[J]. PLoS Pathog, 2023, 19(2):e1011202.DOI:10. 1371/journal. ppat. 1011202.
[15]王雍，王志龙，衣凯宁，等. HTLV-1病毒蛋白Tax和HBZ协同促进成人T细胞白血病发生的机制[J].病毒学报，2019, 35(1):149-157. DOI:10. 13242/j. cnki.bingduxuebao. 003489.
[16]Johnson JM, Nicot C, Fullen J, et al. Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12(I)protein[J].J Virol, 2001, 75(13):6086-6094. DOI:10. 1128/jvi. 75. 13. 6086-6094. 2001.
[17]Gill PS, Harrington W, Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon Alfa and zidovudine[J]. N Engl J Med,1995, 332(26):1744-1748
[18]Nasr R, Mar?ais A, Hermine O, et al. Overview of targeted therapies for adult T-cell leukemia/lymphoma[J]. Methods Mol Biol, 2017, 1582:197-216. DOI:10. 1007/978-1-4939-6872-5_15.
[19]Bazarbachi A, Plumelle Y, Carlos Ramos J, et al. Meta-analysis on the use of zidovudine and interferon-Alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes[J]. J Clin Oncol,2010, 28(27):4177-4183. DOI:10. 1200/jco. 2010. 28. 0669.
[20]Cook LB, Taylor GP. Treatment of adult T-cell leukaemia/lymphoma:is the virus a target?[J]. Curr Opin Infect Dis, 2015, 28(6):583-588. DOI:10. 1097/qco. 0000000000000207.
[21]Mar?ais A, Suarez F, Sibon D, et al. Clinical trials of adult T-cell leukaemia/lymphoma treatment[J]. Leuk Res Treatment, 2012, 2012:932175. DOI:10. 1155/2012/932175.
[22]Cook LB, Phillips AA. How I treat adult T-cell leukemia/lymphoma[J]. Blood, 2021, 137(4):459-470. DOI:10. 1182/blood. 2019004045.
[23]Yamada Y, Tomonaga M, Fukuda H, et al. A new GCSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma:Japan Clinical Oncology Group Study 9303[J]. Br J Haematol, 2001,113(2):375-382. DOI:10. 1046/j. 1365-2141. 2001. 02737. x.
[24]Shimoyama M, Ota K, Kikuchi M, et al.Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin’s lymphoma treated with VEPA or VEPA-M[J]. J Clin Oncol,1988, 6(1):128-141. DOI:10. 1200/jco. 1988. 6. 1. 128.
[25]Abboud C. Allogeneic HSCT for ATL:a good start[J]. Blood, 2012, 120(8):1541-1542. DOI:10. 1182/blood-2012-07-439224.
[26]朱佳琳，唐博，尹玥，等.单倍型异基因造血干细胞移植治疗难治急性型成人T细胞白血病-淋巴瘤1例并文献复习[J].现代肿瘤医学，2022, 30(23):4294-4298.DOI:10. 3969/j. issn. 1672-4992. 2022. 23. 014.
[27]Izutsu K, Makita S, Nosaka K, et al. An open-label,single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma[J]. Blood,2023, 141(10):1159-1168. DOI:10. 1182/blood. 2022016862.
[28]Bazarbachi A, Cwynarski K, Boumendil A, et al.Outcome of patients with HTLV-1-associated adult Tcell leukemia/lymphoma after SCT:a retrospective study by the EBMT LWP[J]. Bone Marrow Transplant, 2014, 49(10):1266-1268. DOI:10. 1038/bmt. 2014. 143.
[29]Kato K, Akashi K. Recent advances in therapeutic approaches for adult T-cell leukemia/lymphoma[J].Viruses, 2015, 7(12):6604-6612. DOI:10. 3390/v7122960.
[30]El Hajj H, El-Sabban M, Hasegawa H, et al. Therapyinduced selective loss of leukemia-initiating activity in murine adult T cell leukemia[J]. J Exp Med, 2010, 207(13):2785-2792. DOI:10. 1084/jem. 20101095.
[31]Ratner L, Harrington W, Feng X, et al. Human T cell leukemia virus reactivation with progression of adult Tcell leukemia-lymphoma[J]. PLoS One, 2009, 4(2):e4420. DOI:10. 1371/journal. pone. 0004420.
[32]Tsukasaki K, Ikeda S, Murata K, et al. Characteristics of chemotherapy-induced clinical remission in long survivors with aggressive adult T-cell leukemia/lymphoma[J]. Leuk Res, 1993, 17(2):157-166.DOI:10. 1016/0145-2126(93)90061-o.
[33]Marino-Merlo F, Mastino A, Grelli S, et al. Future perspectives on drug targeting in adult T cell leukemialymphoma[J]. Front Microbiol, 2018, 9:925. DOI:10. 3389/fmicb. 2018. 00925.
[34]Tsukasaki K, Hermine O, Bazarbachi A, et al.Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma:a proposal from an international consensus meeting[J]. J Clin Oncol, 2009, 27(3):453-459. DOI:10. 1200/jco. 2008. 18. 2428.
[35]Kondo N, Nagano Y, Hasegawa A, et al. Involvement of EZH2 inhibition in lenalidomide and pomalidomidemediated growth suppression in HTLV-1-infected cells[J]. Biochem Biophys Res Commun, 2021, 574:104-109. DOI:10. 1016/j. bbrc. 2021. 08. 051.
[36]Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximabtreated CD20+tumor cells[J]. Clin Cancer Res, 2008,14(14):4650-4657. DOI:10. 1158/1078-0432. ccr-07-4405.
[37]Phillips AA. Lenalidomide in patients with relapsed or refractory HTLV-1 related adult T cell leukemia/lymphoma(ATLL)[J]. Int J Blood Res Disord, 2015,2(1). DOI:10. 23937/2469-5696/1410010.
[38]Ishida T, Fujiwara H, Nosaka K, et al. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia/lymphoma:ATLL-002[J]. J Clin Oncol, 2016, 34(34):4086-4093. DOI:10. 1200/jco. 2016. 67. 7732.
[39]Pise-Masison CA, Franchini G. Hijacking host immunity by the human T-cell leukemia virus type-1:implications for therapeutic and preventive vaccines[J].Viruses, 2022, 14(10):2084. DOI:10. 3390/v14102084.
[40]Oka S, Ono K, Nohgawa M. Effective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapy[J]. Leuk Res Rep, 2019, 11:21-23. DOI:10. 1016/j.lrr. 2019. 04. 001.
[41]Tsukasaki K, Tobinai K. Human T-cell lymphotropic virus type I-associated adult T-cell leukemia-lymphoma:new directions in clinical research[J]. Clin Cancer Res,2014, 20(20):5217-5225. DOI:10. 1158/1078-0432.ccr-14-0572.
[42]Ishida T, Jo T, Takemoto S, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult Tcell leukaemia-lymphoma:a randomized phase II study[J]. Br J Haematol, 2015, 169(5):672-682. DOI:10. 1111/bjh. 13338.
[43]Shimosaki S, Nakahata S, Ichikawa T, et al.Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult Tcell leukemia/lymphoma[J]. Biochem Biophys Res Commun, 2017, 485(1):144-151. DOI:10. 1016/j.bbrc. 2017. 02. 039.
[44]Katz J, Janik JE, Younes A. Brentuximab vedotin(SGN-35)[J]. Clin Cancer Res, 2011, 17(20):6428-6436. DOI:10. 1158/1078-0432. ccr-11-0488.
[45]Uike N, Choi I, Tokoro A, et al. Adult T-cell leukemia-lymphoma successfully treated with 2-chlorodeoxyadenosine[J]. Intern Med, 1998, 37(4):411-413. DOI:10. 2169/internalmedicine. 37. 411.
[46]赵铁军，张熠玲，邹丰，等.成人T细胞白血病治疗进展[J].浙江师范大学学报（自然科学版），2020, 43(2):191-198. DOI:10. 16218/j. issn. 1001-5051. 2020. 02. 012.
[47]Jalili-Nik M, Soltani A, Hashemy SI, et al.Development of potential inhibitors for human Tlymphotropic virus type I integrase enzyme:a molecular modeling approach[J]. Curr Comput Aided Drug Des,2024, 20(1):72-86. DOI:10. 2174/1573409919666230419082839.
[48]Zephyr J, Kurt Yilmaz N, Schiffer CA. Viral proteases:Structure, mechanism and inhibition[J].Enzymes, 2021, 50:301-333. DOI:10. 1016/bs.enz. 2021. 09. 004.
[49]Suehiro Y, Hasegawa A, Iino T, et al. Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study[J]. Br J Haematol, 2015,169(3):356-367. DOI:10. 1111/bjh. 13302.
[50]Kabiri M, Sankian M, Hosseinpour M, et al. The novel immunogenic chimeric peptide vaccine to elicit potent cellular and mucosal immune responses against HTLV-1[J]. Int J Pharm, 2018, 549(1-2):404-414.DOI:10. 1016/j. ijpharm. 2018. 07. 069.
[51]Kabiri M, Sankian M, Sadri K, et al. Robust mucosal and systemic responses against HTLV-1 by delivery of multi-epitope vaccine in PLGA nanoparticles[J]. Eur J Pharm Biopharm, 2018, 133:321-330. DOI:10. 1016/j. ejpb. 2018. 11. 003.
基本信息:
DOI：10.13242/j.cnki.bingduxuebao.004553
中图分类号:R373.1
引用信息:
[1]张洁,陈书畅,郑泽甬,等.抗HTLV-1病毒感染及ATL治疗研究进展[J].病毒学报,2024,40(06):1442-1452.DOI:10.13242/j.cnki.bingduxuebao.004553.
基金信息:
浙大城市学院科研培育基金资助课题（项目号：J-202106）,题目：SARS-CoV-2假病毒感染系统的建立及入侵抑制剂的研究; 国家自然科学基金面上项目（项目号：32370147）,题目：HTLV-1病毒通过调控细胞应激颗粒抑制天然免疫并促进病毒复制的机制研究; 浙大城市学院2024年国家级大学生创新训练项目,题目：抗HTLV-1病毒药物筛选及其分子机制研究~~
2024-01-04
2024
2024-04-02
2024-08-01
2024
1
2024-08-01
2024-08-01
2024-08-01